Literature DB >> 17367951

Small interfering RNA-mediated selective knockdown of Na(V)1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats.

X-W Dong1, S Goregoaker, H Engler, X Zhou, L Mark, J Crona, R Terry, J Hunter, T Priestley.   

Abstract

The biophysical properties of a tetrodotoxin resistant (TTXr) sodium channel, Na(V)1.8, and its restricted expression to the peripheral sensory neurons suggest that blocking this channel might have therapeutic potential in various pain states and may offer improved tolerability compared with existing sodium channel blockers. However, the role of Na(V)1.8 in nociception cannot be tested using a traditional pharmacological approach with small molecules because currently available sodium channel blockers do not distinguish between sodium channel subtypes. We sought to determine whether small interfering RNAs (siRNAs) might be capable of achieving the desired selectivity. Using Northern blot analysis and membrane potential measurement, several siRNAs were identified that were capable of a highly-selective attenuation of Na(V)1.8 message as well as functional expression in clonal ND7/23 cells which were stably transfected with the rat Na(V)1.8 gene. Functional knockdown of the channel was confirmed using whole-cell voltage-clamp electrophysiology. One of the siRNA probes showing a robust knockdown of Na(V)1.8 current was evaluated for in vivo efficacy in reversing an established tactile allodynia in the rat chronic constriction nerve-injury (CCI) model. The siRNA, which was delivered to lumbar dorsal root ganglia (DRG) via an indwelling epidural cannula, caused a significant reduction of Na(V)1.8 mRNA expression in lumbar 4 and 5 (L4-L5) DRG neurons and consequently reversed mechanical allodynia in CCI rats. We conclude that silencing of Na(V)1.8 channel using a siRNA approach is capable of producing pain relief in the CCI model and further support a role for Na(V)1.8 in pathological sensory dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17367951     DOI: 10.1016/j.neuroscience.2007.01.054

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  42 in total

1.  Modulation of Nav1.8 by Lysophosphatidic Acid in the Induction of Bone Cancer Pain.

Authors:  Hai-Li Pan; Ben-Long Liu; Wei Lin; Yu-Qiu Zhang
Journal:  Neurosci Bull       Date:  2016-09-09       Impact factor: 5.203

Review 2.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 3.  Sodium channels and pain: from toxins to therapies.

Authors:  Fernanda C Cardoso; Richard J Lewis
Journal:  Br J Pharmacol       Date:  2017-09-02       Impact factor: 8.739

Review 4.  Breaking barriers to novel analgesic drug development.

Authors:  Ajay S Yekkirala; David P Roberson; Bruce P Bean; Clifford J Woolf
Journal:  Nat Rev Drug Discov       Date:  2017-06-09       Impact factor: 84.694

Review 5.  Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Authors:  Lisa Gherardini; Giuseppe Bardi; Mariangela Gennaro; Tommaso Pizzorusso
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

6.  Structural determinants of drugs acting on the Nav1.8 channel.

Authors:  Liam E Browne; Frank E Blaney; Shahnaz P Yusaf; Jeff J Clare; Dennis Wray
Journal:  J Biol Chem       Date:  2009-02-19       Impact factor: 5.157

7.  PKCepsilon-dependent potentiation of TTX-resistant Nav1.8 current by neurokinin-1 receptor activation in rat dorsal root ganglion neurons.

Authors:  Chun-Lei Cang; Hua Zhang; Yu-Qiu Zhang; Zhi-Qi Zhao
Journal:  Mol Pain       Date:  2009-06-30       Impact factor: 3.395

8.  An in vivo tethered toxin approach for the cell-autonomous inactivation of voltage-gated sodium channel currents in nociceptors.

Authors:  Annika S Stürzebecher; Jing Hu; Ewan St John Smith; Silke Frahm; Julio Santos-Torres; Branka Kampfrath; Sebastian Auer; Gary R Lewin; Inés Ibañez-Tallon
Journal:  J Physiol       Date:  2010-03-22       Impact factor: 5.182

9.  Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain.

Authors:  E Sloane; S Langer; B Jekich; J Mahoney; T Hughes; M Frank; W Seibert; G Huberty; B Coats; J Harrison; D Klinman; S Poole; S Maier; K Johnson; R Chavez; L R Watkins; L Leinwand; E Milligan
Journal:  Gene Ther       Date:  2009-07-02       Impact factor: 5.250

10.  Increased peripheral nerve excitability and local NaV1.8 mRNA up-regulation in painful neuropathy.

Authors:  Devang Kashyap Thakor; Audrey Lin; Yoshizo Matsuka; Edward M Meyer; Supanigar Ruangsri; Ichiro Nishimura; Igor Spigelman
Journal:  Mol Pain       Date:  2009-03-25       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.